265 related articles for article (PubMed ID: 25091862)
1. Prostate cancer risk assessment tools in an unscreened population.
Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
[TBL] [Abstract][Full Text] [Related]
2. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
[TBL] [Abstract][Full Text] [Related]
4. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
5. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
6. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
7. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
8. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
9. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
10. Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.
Foley RW; Lundon DJ; Murphy K; Murphy TB; Galvin DJ; Watson RW
Ir J Med Sci; 2015 Sep; 184(3):701-6. PubMed ID: 25843017
[TBL] [Abstract][Full Text] [Related]
11. External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.
Zhu Y; Wang JY; Shen YJ; Dai B; Ma CG; Xiao WJ; Lin GW; Yao XD; Zhang SL; Ye DW
Asian J Androl; 2012 Sep; 14(5):738-44. PubMed ID: 22561907
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
[TBL] [Abstract][Full Text] [Related]
14. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study.
De Nunzio C; Lombardo R; Tema G; Alkhatatbeh H; Gandaglia G; Briganti A; Tubaro A
Urol Oncol; 2018 Aug; 36(8):364.e1-364.e7. PubMed ID: 29880458
[TBL] [Abstract][Full Text] [Related]
15. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
16. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
Louie KS; Seigneurin A; Cathcart P; Sasieni P
Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
[TBL] [Abstract][Full Text] [Related]
17. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
[TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract][Full Text] [Related]
19. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
Loeb S; Shin SS; Broyles DL; Wei JT; Sanda M; Klee G; Partin AW; Sokoll L; Chan DW; Bangma CH; van Schaik RHN; Slawin KM; Marks LS; Catalona WJ
BJU Int; 2017 Jul; 120(1):61-68. PubMed ID: 27743489
[TBL] [Abstract][Full Text] [Related]
20. Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?
Lee DH; Jung HB; Park JW; Kim KH; Kim J; Lee SH; Chung BH
Yonsei Med J; 2013 May; 54(3):665-71. PubMed ID: 23549812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
